LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

Search

Simulations Plus Inc

Открыт

СекторЗдравоохранение

20.68 3.82

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

19.83

Макс.

20.74

Ключевые показатели

By Trading Economics

Доход

-70M

-67M

Продажи

-2.1M

20M

P/E

Средняя по отрасли

48.528

80.03

Дивидендная доходность

0.48

Рентабельность продаж

-330.585

Сотрудники

243

EBITDA

327K

5.3M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+0.74% upside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

0.48%

2.29%

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-7M

344M

Предыдущая цена открытия

16.86

Предыдущая цена закрытия

20.68

Новостные настроения

By Acuity

56%

44%

310 / 374 Рейтинг в Healthcare

Simulations Plus Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

3 дек. 2025 г., 23:21 UTC

Отчет
Приобретения, слияния, поглощения

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 дек. 2025 г., 23:14 UTC

Приобретения, слияния, поглощения

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 дек. 2025 г., 22:01 UTC

Главные движущие силы рынка

Costco Wholesale Reports Higher Monthly Sales

3 дек. 2025 г., 21:38 UTC

Отчет

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 дек. 2025 г., 23:59 UTC

Обсуждения рынка

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 дек. 2025 г., 23:49 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

3 дек. 2025 г., 23:49 UTC

Обсуждения рынка

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 дек. 2025 г., 23:49 UTC

Обсуждения рынка

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 дек. 2025 г., 23:13 UTC

Обсуждения рынка

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 дек. 2025 г., 23:10 UTC

Отчет

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 дек. 2025 г., 23:08 UTC

Обсуждения рынка

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 дек. 2025 г., 23:06 UTC

Приобретения, слияния, поглощения

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 дек. 2025 г., 22:59 UTC

Приобретения, слияния, поглощения

EQB to Buy PC Financial From Loblaw for About $573.5M

3 дек. 2025 г., 22:45 UTC

Обсуждения рынка

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 дек. 2025 г., 22:20 UTC

Отчет

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 дек. 2025 г., 22:19 UTC

Отчет

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 дек. 2025 г., 22:17 UTC

Отчет

Salesforce Working to Add Voice to Agentforce, CEO Says

3 дек. 2025 г., 22:16 UTC

Отчет

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 дек. 2025 г., 22:15 UTC

Отчет

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 дек. 2025 г., 22:10 UTC

Приобретения, слияния, поглощения

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 дек. 2025 г., 22:09 UTC

Приобретения, слияния, поглощения

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 дек. 2025 г., 21:50 UTC

Обсуждения рынка

Auto & Transport Roundup: Market Talk

3 дек. 2025 г., 21:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

3 дек. 2025 г., 21:49 UTC

Отчет

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 дек. 2025 г., 21:23 UTC

Отчет

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 дек. 2025 г., 21:19 UTC

Отчет

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 дек. 2025 г., 21:06 UTC

Отчет

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 дек. 2025 г., 21:04 UTC

Отчет

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 дек. 2025 г., 21:04 UTC

Отчет

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 дек. 2025 г., 21:03 UTC

Отчет

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Сравнение c конкурентами

Изменение цены

Simulations Plus Inc Прогноз

Целевая цена

By TipRanks

0.74% рост

Прогноз на 12 месяцев

Средняя 20.5 USD  0.74%

Максимум 25 USD

Минимум 16 USD

Основано на мнении 5 аналитиков Wall Street, спрогнозировавших целевые цены для Simulations Plus Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

5 ratings

3

Покупка

2

Удержание

0

Продажа

Настроения

By Acuity

310 / 374Рейтинг в Здравоохранение

Новостные настроения

Свидетельства нисходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat